Ferhat Meziani, MD, PhD, Service de Réanimation Médicale - Nouvel Hôpital Civil, 1, place de l'Hôpital, F-67091 Strasbourg cedex, France, Tel.: +33 369 550 434, Fax: +33 369 551 859, E-mail:
Thromb Haemost. 2014 Jan;111(1):154-64. doi: 10.1160/TH13-04-0313. Epub 2013 Oct 10.
Circulating microparticles play a pro-inflammatory and procoagulant detrimental role in the vascular dysfunction of septic shock. It was the objective of this study to investigate mechanisms by which a pharmacological modulation of microparticles could affect vascular dysfunction in a rat model of septic shock. Septic or sham rats were treated by activated protein C (aPC) and resuscitated during 4 hours. Their microparticles were harvested and inoculated to another set of healthy recipient rats. Haemodynamic parameters were monitored, circulating total procoagulant microparticles assessed by prothrombinase assay, and their cell origin characterised. Mesenteric resistance arteries, aorta and heart were harvested for western blotting analysis. We found that a) the amount and phenotype of circulating microparticles were altered in septic rats with an enhanced endothelial, leucocyte and platelet contribution; b) aPC treatment significantly reduced the generation of leucocyte microparticles and norepinephrine requirements to reach the mean arterial pressure target in septic rats; c) Microparticles from untreated septic rats, but not from aPC-treated ones, significantly reduced the healthy recipients' mean arterial pressure; d) Microparticle thromboxane content and aPC activity were significantly increased in aPC-treated septic rats. In inoculated naïve recipients, microparticles from aPC-treated septic rats prompted reduced NF-κB and cyclooxygenase-2 arterial activation, blunted the generation of pro-inflammatory iNOS and secondarily increased platelet and endothelial microparticles. In conclusion, in this septic shock model, increased circulating levels of procoagulant microparticles led to negative haemodynamic outcomes. Pharmacological treatment by aPC modified the cell origin and levels of circulating microparticles, thereby limiting vascular inflammation and favouring haemodynamic improvement.
循环的微颗粒在脓毒性休克的血管功能障碍中发挥促炎和促凝的有害作用。本研究旨在探讨药物调节微颗粒如何影响脓毒性休克大鼠模型的血管功能障碍的机制。脓毒症或假手术大鼠用活化蛋白 C(APC)治疗,并在 4 小时内复苏。收获它们的微颗粒并接种到另一组健康的受体大鼠中。监测血流动力学参数,通过凝血酶原酶测定法评估循环总促凝微颗粒,并对其细胞来源进行特征分析。采集肠系膜阻力动脉、主动脉和心脏进行 Western blot 分析。我们发现:a)在脓毒症大鼠中,循环微颗粒的数量和表型发生改变,内皮细胞、白细胞和血小板的贡献增加;b)APC 治疗显著减少了白细胞微颗粒的生成,并降低了脓毒症大鼠达到平均动脉压目标所需的去甲肾上腺素量;c)未经处理的脓毒症大鼠的微颗粒,但不是 APC 处理的微颗粒,显著降低了健康受体的平均动脉压;d)APC 处理的脓毒症大鼠的微颗粒血栓素含量和 APC 活性显著增加。在接种的未处理受体中,来自 APC 处理的脓毒症大鼠的微颗粒促使 NF-κB 和环氧化酶-2 动脉激活减少,促炎 iNOS 的生成减弱,血小板和内皮微颗粒的生成增加。总之,在这种脓毒性休克模型中,促凝微颗粒循环水平的增加导致了负性血流动力学结果。APC 的药物治疗改变了循环微颗粒的细胞来源和水平,从而限制了血管炎症并促进了血流动力学的改善。